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Figure 1. HTA Report Selection
• To conduct a review of cervical cancer screening HTAs to understand how new technologies are evaluated.
• To assess what metrics are used to assess technology value within the context of a cervical cancer screening program.
Table 1. Search Strategy and Information Sources
• 18 HTAs from 9 countries met inclusion criteria (Figure 1 ).
• Five technology types identified: 2 cytology tests (conventional cytology (CC), liquid-based cytology (LBC)), 2 Human papillomavirus (HPV) molecular tests, and 1 computer-assisted screening system. • All 18 HTAs evaluated test sensitivity and specificity as the primary measure of clinical effectiveness.
• Several HTAs also included other screening program considerations (lab efficiency, specimen quality).
Type of Economic Analysis
• A cost-effectiveness analysis was included in 11 HTA reports.
• 73% (8/11) of recommendations were derived from primary economic analysis (using a countryspecific model) while 27% (3/11) of reports referred to previously published literature to make a costeffectiveness recommendation.
• All eight HTAs reporting primary economic analysis incorporated sensitivity analyses to test various screening intervals.
Liquid-based Cytology (LBC) (Primary Screen)
• Seven reports addressed cost-effectiveness of LBC compared to CC. Of these, 86% (6/7) concluded that LBC can be a cost-effective strategy compared to CC at specified intervals. • While effective cervical cancer screening programs have contributed to steadily declining mortality rates in many countries, cervical cancer is still a major contributor to cancer-related death around the world 1 .
• Although conventional cytology (PAP smear) is the most common cervical screening method globally, a number of new technologies with the potential for improved disease detection have become available over the last decade.
• Understanding the criteria for recommending new cervical cancer screening algorithms and use of new technologies can inform future research priorities for both government bodies and manufacturers.
• Many country-level health technology assessment (HTA) bodies have completed evidence reviews and decision models to inform cervical cancer screening recommendations, however these data and decisions have not been collectively analyzed and compared.
• The search strategy and key information sources are detailed in Table 1 .
• HTA records were screened to access whether the primary report focus was cervical cancer screening, and were then assessed for eligibility.
• Studies were excluded if no English summary was available.
• Topics, technologies, clinical results, primary or literature-based economic analysis, and incremental cost-effectiveness ratios (ICERs) were abstracted and analyzed. HPV DNA Test
•LBC may yield a lower proportion of unsatisfactory slides.
